We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

113 hedge funds and large institutions have $285M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

5% less call options, than puts

Call options by funds: $390K | Put options by funds: $410K

9% less funds holding

Funds holding: 124 → 113 (-11)

17% less capital invested

Capital invested by funds: $343M → $285M (-$57.3M)

17% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 41

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

Holders
113
Holders Change
-11
Holders Change %
-8.87%
% of All Funds
1.78%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
10
Increased
34
Reduced
41
Closed
20
Calls
$390K
Puts
$410K
Net Calls
-$20K
Net Calls Change
-$415K

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$13M
2
Morgan Stanley
Morgan Stanley
New York
+$10.6M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$8.92M
4
ACP
Acuta Capital Partners
California
+$4.89M
5
CAC
Cowen and Company
New York
+$4.09M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$11.4M
2
TGI
TRV GP II
Massachusetts
-$9.62M
3
CS
Candriam SCA
Luxembourg
-$2.82M
4
Goldman Sachs
Goldman Sachs
New York
-$2.34M
5
Barclays
Barclays
United Kingdom
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
APA
101
American Portfolios Advisors
New York
$11.2K – – –
BG
102
Bollard Group
Massachusetts
$7K – – –
CB
103
Community Bank
New York
$7K – – –
TSWM
104
Tyler-Stone Wealth Management
Ohio
$5K – – –
Nisa Investment Advisors
105
Nisa Investment Advisors
Missouri
$4K – – –
Koshinski Asset Management
106
Koshinski Asset Management
Illinois
$2.04K – – –
ACM
107
Aquatic Capital Management
Illinois
$2K -$62.7K -8,800 -97%
SCM
108
Silverarc Capital Management
Massachusetts
$1.69K +$17.9K +2,518 +1%
Daiwa Securities Group
109
Daiwa Securities Group
Japan
$1K – – –
Osaic Holdings
110
Osaic Holdings
Arizona
$1K – – –
Simplex Trading
111
Simplex Trading
Illinois
$1K +$2.05K +287 New
MGB
112
Mass General Brigham
Massachusetts
$1K +$149K +20,957 New
WP
113
Woodline Partners
California
– -$11.4M -1,359,528 Closed
CS
114
Candriam SCA
Luxembourg
– -$2.82M -337,398 Closed
GIM
115
Granahan Investment Management
Massachusetts
– -$1.41M -168,424 Closed
YMRC
116
Yorktown Management & Research Company
Virginia
– -$1.15M -137,300 Closed
Ameriprise
117
Ameriprise
Minnesota
– -$895K -107,198 Closed
Millennium Management
118
Millennium Management
New York
– -$581K -69,540 Closed
D.E. Shaw & Co
119
D.E. Shaw & Co
New York
– -$574K -68,776 Closed
FIM
120
Freedom Investment Management
Connecticut
– -$417K -49,959 Closed
B
121
Bailard
California
– -$267K -31,952 Closed
Stifel Financial
122
Stifel Financial
Missouri
– -$212K -25,374 Closed
NA
123
Navellier & Associates
Nevada
– -$206K -24,611 Closed
EGM
124
Engineers Gate Manager
New York
– -$154K -18,500 Closed
DTL
125
Dynamic Technology Lab
Singapore
– -$150K -17,913 Closed
2 3 4
5
6

JNCE Hedge Fund Activity: Q1 2022 in Review

113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2022, worth a combined $285M — down 17% from $343M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of JNCE and 10 opened new positions — a net loss of 10 holders — while 41 trimmed existing stakes and 34 added.

The largest buyer was RTW Investments, adding an estimated $13M. The largest seller was Woodline Partners, exiting entirely with an estimated $11.4M sold.

  • 113 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2022, down from 124 in Q4 2021.
  • Funds reported $285M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2022, down 17% quarter-over-quarter.
  • 10 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2022 and 20 closed out, a net change of -10 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2022 was RTW Investments, an estimated $13M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2022 was Woodline Partners, an estimated $11.4M sold.

Based on aggregated 13F filings for Q1 2022.